Nova Eye Medical Revenue and Competitors
Estimated Revenue & Valuation
- Nova Eye Medical's estimated annual revenue is currently $15.3M per year.
- Nova Eye Medical's estimated revenue per employee is $251,000
- Nova Eye Medical's total funding is $3M.
Employee Data
- Nova Eye Medical has 61 Employees.
- Nova Eye Medical grew their employee count by 22% last year.
Nova Eye Medical's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Marketing | Reveal Email/Phone |
2 | VP Corporate Accounts | Reveal Email/Phone |
3 | Quality & Regulatory | Reveal Email/Phone |
Nova Eye Medical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $24.1M | 96 | 19% | N/A | N/A |
#2 | $9.5M | 38 | 12% | N/A | N/A |
#3 | $4M | 16 | -11% | N/A | N/A |
#4 | $7.8M | 31 | -3% | N/A | N/A |
#5 | $5M | 20 | -5% | N/A | N/A |
#6 | $49.9M | 199 | -8% | N/A | N/A |
#7 | $16.8M | 67 | -17% | $63.2M | N/A |
#8 | $9.3M | 37 | -7% | N/A | N/A |
#9 | $36.6M | 146 | 22% | N/A | N/A |
#10 | $64.3M | 205 | 3% | $502M | N/A |
What Is Nova Eye Medical?
Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary glaucoma treatment technologies. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications, and the Molteno3® glaucoma drainage device for cases of severe and complex glaucoma.
keywords:N/A$3M
Total Funding
61
Number of Employees
$15.3M
Revenue (est)
22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.8M | 61 | 27% | N/A |
#2 | $18.1M | 62 | 0% | N/A |
#3 | $8.1M | 62 | 7% | N/A |
#4 | $8.1M | 62 | -19% | N/A |
#5 | $13.7M | 62 | 3% | N/A |